CAS No.: 1353550-13-6
Olmutinib/奥莫替尼 Catalog No. CSN17738
Synonyms: HM61713, BI 1482694;BI-1482694;HM-61713
Olmutinib inhibits EGFR with IC50 values of 9.2 nM and 10 nM in HCC827 (expressing EGFR-del 19) and H1975 (expressing EGFR-L858R/T790M) cell respectively. It is a new targeted drug for the treatment of mutation-positive NSCLC.
| 规格 | 价格 | 促销价格 | 库存 | 数量 |
|---|
400-920-2911
sales@csnpharm.cn
tech@csnpharm.cn
纯度 & 质量文件
批次:
靶点选择性
生物活性
- 描述
- 临床研究
NCT号 适应症或疾病 临床期 招募状态 预计完成时间 地点 NCT02722161 Healthy Phase 1 Completed - Netherlands ... more >> 1370.7.31001 Boehringer Ingelheim Investigational Site Zuidlaren, Netherlands Collapse << NCT01588145 Non Small Cell Lung Cancer Phase 1 Phase 2 Completed - Korea, Republic of ... more >> Seoul, Korea, Republic of Collapse << NCT02485652 Non Small Cell Lung Cancer Phase 2 Active, not recruiting December 2018 - - 更多
- 参考文献
- [1] Liao BC, Lin CC, et al. Optimal management of EGFR-mutant non-small cell lung cancer with disease progression on first-line tyrosine kinase inhibitor therapy. Lung Cancer. 2017 Aug;110:7-13.
- [2] Passaro A, Guerini-Rocco E, et al. Targeting EGFR T790M mutation in NSCLC: From biology to evaluation and treatment. Pharmacol Res. 2017 Mar;117:406-415.
实验方案
- 计算器
- 储存液制备
技术信息
| CAS号 | 1353550-13-6 | 储存条件 |
|
|||||||
| 分子式 | C26H26N6O2S | 运输 | 蓝冰 | |||||||
| 分子量 | 486.59 | 别名 | HM61713, BI 1482694;BI-1482694;HM-61713;奥莫替尼 | |||||||
| 溶解度 |
|
动物实验配方 |
